LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis GBX 184.50 +4.50 (+2.50%) As of 05/2/2025 12:20 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Hemogenyx Pharmaceuticals Stock (LON:HEMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HEMO alerts:Sign Up Key Stats Today's Range 180.50▼ 191.5050-Day Range 167.25▼ 321.9052-Week Range 160▼ 1,200Volume37,062 shsAverage Volume28,867 shsMarket Capitalization£6.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.Read More… Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HEMO Stock News HeadlinesTRADING UPDATES: Golden Rock secures refinancing; tinyBuild makes saleApril 4, 2025 | lse.co.ukHemogenyx Pharmaceuticals Boosts Clinical Trials with £340,000 FundraisingJanuary 8, 2025 | markets.businessinsider.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 3, 2025 | Porter & Company (Ad)Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000January 8, 2025 | finance.yahoo.comHemogenyx Pharmaceuticals Announces Key Corporate ChangesJanuary 2, 2025 | markets.businessinsider.comHemogenyx opens first clinical site for leukaemia therapy trialDecember 30, 2024 | lse.co.ukHemogenyx Pharmaceuticals begins patient recruitment at first clinical trial siteDecember 30, 2024 | uk.investing.comHemogenyx Pharmaceuticals PLC Announces CBR Macrophage Delivery UpdateDecember 6, 2024 | finance.yahoo.comSee More Headlines HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed this year? Hemogenyx Pharmaceuticals' stock was trading at GBX 402 at the start of the year. Since then, HEMO shares have decreased by 54.1% and is now trading at GBX 184.50. View the best growth stocks for 2025 here. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) announced its quarterly earnings data on Monday, April, 28th. The company reported ($181.10) earnings per share for the quarter. How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings4/28/2025Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HEMO Previous SymbolLON:SILF CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,890.55 Net MarginsN/A Pretax MarginN/A Return on Equity-80.66% Return on Assets-37.79% Debt Debt-to-Equity Ratio90.87 Current Ratio4.38 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 90.22 per share Price / Cash Flow2.05 Book ValueGBX 0.25 per share Price / Book748.91Miscellaneous Outstanding Shares3,564,489Free FloatN/AMarket Cap£6.58 million OptionableNot Optionable Beta3.14 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:HEMO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.